Deucravacitinib is a potent Type I IFN inhibitor and indirectly inhibits IFNγ; however, infection rates are low relative to JAK1,2,3 inhibitors due to optimized dosing that sufficiently controls inflammation without complete pathway inhibition (26, 28). Here, JAK1 is linked to infection.